NCT06069661撤回不适用
A Prospective, Single-arm, Multicenter Feasibility Trial to Evaluate the Safety and Performance of the F2 Filter and Delivery System Used for Embolic Protection During Transcatheter Aortic Valve Replacement
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 入组人数
- 25
- 试验地点
- 2
- 主要终点
- Major adverse cardiac and cerebrovascular events (MACCE)
研究概览
简要总结
The goal of this clinical trial is to learn about the safety and performance of the F2 device for cerebral embolic protection in participants with symptomatic aortic stenosis undergoing a Transcatheter Aortic Valve replacement procedure.
详细描述
The goal of this clinical trial is to learn about the safety and performance of the F2 device for cerebral embolic protection in participants with symptomatic aortic stenosis undergoing a Transcatheter Aortic Valve replacement procedure. The F2 device is inserted via a transfemoral approach and positioned in the aorta to cover and protect the three great cerebral vessels from any debris released during the valve replacement procedure. The F2 device remains in place during the aortic valve replacement procedure. After the valve is placed, the F2 device is removed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 22 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 22 years.
- •The patient meets the established criteria and indications for commercially available TAVR (Edwards/Medtronic) for transfemoral access.
- •Modified Rankin Scale (mRS) 0 or 1 at screening.
- •Montreal Cognitive Assessment (MoCA) score ≥ 26 at screening.
- •The patient is willing and able to comply with protocol-specified follow-up evaluations.
- •6 The patient or legally authorized representative is able and willing to provide written informed consent.
排除标准
- •Subjects are not eligible for the study if any of the following criteria are present:
- •Contraindications to MRI (e.g., subjects with MR unsafe implants including implantable temporary or permanent pacemaker or defibrillator, metal implants in field of view, metallic fragments, clips, or devices in the brain or eye before TAVR procedure, or claustrophobia).
- •Severe peripheral arterial, abdominal aortic, or thoracic aortic disease that precludes delivery sheath vascular access or filter deployment.
- •Patients in whom the aortic arch is heavily calcified, severely atheromatous, or severely tortuous.
- •Ascending aortic diameter > 38 mm or transverse aortic diameter > 27 mm.
- •Evidence of an acute myocardial infarction within 1 month before TAVR.
- •Pre-existing prosthetic heart valve or prosthetic ring in any position.
- •Known intracardiac thrombus.
- •Severe allergy or known hypersensitivity or contraindication to aspirin, heparin/bivalirudin, clopidogrel, nitinol, stainless steel alloy, and/or contrast sensitivity that cannot be adequately pre-medicated.
- •History of bleeding diathesis or coagulopathy or patients in whom anti-platelet and/or anticoagulant therapy is contraindicated.
- •Patients who refuse blood transfusion.
- •Active peptic ulcer or history of upper gastrointestinal (GI) bleeding within the prior 3 months.
- •Recent (within 6 months) CVA or a TIA.
- •Renal insufficiency (creatinine > 2.5 mg/dL or GFR < 30) and/or renal replacement therapy at the time of screening.
- •Patients with hepatic failure (Child-Pugh class C).
- •Patients with hypercoagulable states that cannot be corrected by additional periprocedural heparin.
- •Patients presenting with cardiogenic shock or requiring vasopressor or inotropic support at the time of the index procedure.
- •Severe ventricular dysfunction with left ventricular ejection fraction (LVEF) < 20%.
- •Life expectancy < 12 months.
- •Currently participating in an investigational drug or another device study that has not completed the initial primary endpoint evaluation (e.g., long term follow-up study/continued access study subjects are able to be included).
- •Subjects who have had treatment with any other investigational device within 30 days prior to study enrollment.
- •Planned surgery or invasive procedure within 30 days following the index procedure (TAVR with F2 Filter).
- •Patients planned to undergo any other cardiac surgical or interventional procedure (e.g., concurrent coronary revascularization) during the TAVR procedure or within 10 days prior to the TAVR procedure. NOTE: Balloon valvuloplasty during TAVR is permitted. Diagnostic cardiac catheterization is permitted within 10 days prior to the TAVR procedure.
- •Patients with known mental or physical illness or known history of substance abuse that may cause non-compliance with the protocol or confound the data interpretation.
- •Females who are pregnant or nursing or plan to become pregnant during their participation in the study. Female subjects of child-bearing potential must have a negative pregnancy test at screening.
- •Any other condition that in the opinion of the investigator, precludes study participation or poses a significant hazard to the patient.
结局指标
主要结局
Major adverse cardiac and cerebrovascular events (MACCE)
时间窗: 30 day
Major adverse cardiac and cerebrovascular events
次要结局
- Location of new Lesions(8-72 hours)
- Montreal Cognitive Assessment(30 day)
- Number of new Lesions(8-72 hours)
- Modified Rankin Score(30 day)
- Average Individual new Lesion volume(8-72 hours)
- Territory of new Lesions(8-72 hours)
- Total new lesion volume(8-72 hours)
- Performance(Intra-procedure)
- National Institute of Health Stroke Scale (NIHSS)(30 day)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Multicenter Feasibility Trial of the F2 Filter and Delivery System for Embolic Protection During TAVRAortic StenosisNCT05893082EnCompass Technologies, Inc.18
招募中
早期 1 期
Feasibility Trial of the F2 Filter and Delivery System for Embolic Protection During TAVRAortic StenosisNCT05866640EnCompass Technologies, Inc.10
尚未招募
2 期
Hepatic Artery Infusion of Adebrelimab Combined With Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma With Failure of Systemic Therapy Combined With Interventional TherapyHepatocellular CarcinomaNCT05975463HuiKai Li30
已完成
不适用
Late Feasibility Study to Evaluate Safety and Efficacy of AWAK PD Device in Subjects With ESKD.Chronic Kidney DiseasesNCT05827588AWAK Technologies Pte Ltd12
Unknown
4 期
Prospective, Multicenter Study of the Second Generation Antimicrobial Graft in the Abdominal PositionAneurysmal Disease of the Abdominal AortaOcclusive Disease of the Abdominal AortaNCT00824109Datascope Corp.60